Jana Pöttgen1, Stephanie Lau1, Iris Penner1, Christoph Heesen1, Steffen Moritz1. 1. Institute of Neuroimmunology and Multiple Sclerosis and Department of Neurology (JP, SL, CH) and Department of Psychiatry and Psychotherapy (SM), University Medical Center, Hamburg-Eppendorf, Hamburg, Germany; and Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland (IP).
Abstract
BACKGROUND:Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system of potential autoimmune origin that is frequently associated with psychological disorders and cognitive deficits, as well as with fatigue, stress, and psychosocial burden. These factors often cause decreased quality of life, social withdrawal, and unemployment. We describe the development of a cognitive-behavioral group intervention based on the concept of metacognition and evaluation of the feasibility and acceptance of the program as a rehabilitation tool. METHODS:Metacognitive Training in MS (MaTiMS) consists of six modules, each 90 minutes in duration. We tested acceptance and design of the program in six focus groups (entire sample, n = 27). Framework analysis of transcripts was used to identify key topics and categories. Program modules were revised in accordance with appropriate recommendations of focus group members. We subsequently evaluated MaTiMS in two groups (n = 5, n = 6) in a rehabilitation center. Neuropsychological functioning as well as coping self-efficacy, depression, stress, perceived cognitive deficit, fatigue, andquality of life were assessed. Acceptance of MaTiMS from the patient perspective was also studied. RESULTS: The modules were highly accepted by patients. Pre-post assessments showed significant improvements in the Coping Self Efficacy Scale (P = .007), the Würzburger Fatigue Inventory for MS Score (P = .028), and the Hamburg Quality of Life Questionnaire in Multiple Sclerosis Mood subscale (P = .046). CONCLUSIONS: These preliminary results suggest that MaTiMS represents a feasible psychological group training program that may foster improvements in self-efficacy, fatigue, and mood. The next step will be an evaluation of the program in a randomized controlled trial.
RCT Entities:
BACKGROUND:Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system of potential autoimmune origin that is frequently associated with psychological disorders and cognitive deficits, as well as with fatigue, stress, and psychosocial burden. These factors often cause decreased quality of life, social withdrawal, and unemployment. We describe the development of a cognitive-behavioral group intervention based on the concept of metacognition and evaluation of the feasibility and acceptance of the program as a rehabilitation tool. METHODS: Metacognitive Training in MS (MaTiMS) consists of six modules, each 90 minutes in duration. We tested acceptance and design of the program in six focus groups (entire sample, n = 27). Framework analysis of transcripts was used to identify key topics and categories. Program modules were revised in accordance with appropriate recommendations of focus group members. We subsequently evaluated MaTiMS in two groups (n = 5, n = 6) in a rehabilitation center. Neuropsychological functioning as well as coping self-efficacy, depression, stress, perceived cognitive deficit, fatigue, and quality of life were assessed. Acceptance of MaTiMS from the patient perspective was also studied. RESULTS: The modules were highly accepted by patients. Pre-post assessments showed significant improvements in the Coping Self Efficacy Scale (P = .007), the Würzburger Fatigue Inventory for MS Score (P = .028), and the Hamburg Quality of Life Questionnaire in Multiple Sclerosis Mood subscale (P = .046). CONCLUSIONS: These preliminary results suggest that MaTiMS represents a feasible psychological group training program that may foster improvements in self-efficacy, fatigue, and mood. The next step will be an evaluation of the program in a randomized controlled trial.
Authors: R Bakshi; Z A Shaikh; R S Miletich; D Czarnecki; J Dmochowski; K Henschel; V Janardhan; N Dubey; P R Kinkel Journal: Mult Scler Date: 2000-06 Impact factor: 6.312
Authors: Jana Pöttgen; Isabel Dziobek; Susan Reh; Christoph Heesen; Stefan M Gold Journal: J Neurol Neurosurg Psychiatry Date: 2013-01-11 Impact factor: 10.154
Authors: Kirsten van Kessel; Rona Moss-Morris; Ernest Willoughby; Trudie Chalder; Malcolm H Johnson; Elizabeth Robinson Journal: Psychosom Med Date: 2008-02-06 Impact factor: 4.312
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Maria Janina Wendebourg; Lena Katharina Feddersen; Stephanie Lau; Sascha Köpke; Rona Moss-Morris; Christoph Heesen; Jana Pöttgen Journal: Int J MS Care Date: 2016 May-Jun
Authors: Paolla Gabrielle Nascimento Novais; Karla de Melo Batista; Eliane da Silva Grazziano; Maria Helena Costa Amorim Journal: Rev Lat Am Enfermagem Date: 2016-09-01
Authors: Nicole Krause; Karin Riemann-Lorenz; Tanja Steffen; Anne Christin Rahn; Jana Pöttgen; Jan-Patrick Stellmann; Sascha Köpke; Tim Friede; Andrea Icks; Markus Vomhof; Herbert Temmes; Markus van de Loo; Stefan M Gold; Christoph Heesen Journal: BMJ Open Date: 2021-02-16 Impact factor: 2.692